Pharma Stocks
-
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After PALSONIFY’s EU Approval And Global Expansion Progress
Crinetics Pharmaceuticals (CRNX) has been in focus after the European Commission approved PALSONIFY, its once daily oral treatment for acromegaly,…
Read More » -
How Investors Are Reacting To Eisai (TSE:4523) Leaning On Leqembi After Fresh Sales Update
Eisai Co., Ltd. recently reported preliminary first-quarter 2026 sales of ¥26.2 billion, alongside fiscal 2025 revenue of ¥88 billion from its Alzheimer’s…
Read More » -
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma
Over the last year, a good number of insiders have significantly increased their holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT). This…
Read More » -
Piramal Pharma Ltd Reports Flat Quarterly Financial Trend…
Quarterly Financial Performance Overview In the quarter ended March 2026, Piramal Pharma posted net sales of ₹2,751.77 crores, marking a…
Read More » -
3 ASX Penny Stocks With Over A$90M Market Cap
The Australian share market is experiencing a challenging period, with a recent downturn marking its seventh consecutive day of declines.…
Read More » -
How CREXONT’s Positive Phase 4 Data and Reaffirmed Outlook Could Shape Amneal Pharmaceuticals (AMRX) Investors
In April 2026, Amneal Pharmaceuticals reported positive interim Phase 4 ELEVATE-PD data showing CREXONT delivered improved “Good On” time, reduced…
Read More » -
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) will be reporting results this Monday after the bell. Here’s what investors should know.…
Read More » -
Billionaire Tom Steyer Likes This Pharma Stock
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ranks 6th on…
Read More » -
Billionaire Tom Steyer Admires This Pharma Stock
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Liquidia Corporation (NASDAQ:LQDA) ranks 1st on this…
Read More » -
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Ziihera Priority Review Milestone
Jazz Pharmaceuticals (JAZZ) is back in focus after US regulators accepted a priority review of its supplemental biologics application for…
Read More »